Maya A. Marzouk

Maya A. Marzouk

Auto-generated profile, based on publicly available information

Maya A. Marzouk

Yale Child Study Center at Yale School of Medicine, New Haven, Connecticut, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
MMMaya Marzouk
Maya Marzouk
ESElizabeth K. Seng
Elizabeth K. Seng

1 June 2024 in Neurology Clinical Practice
Verified
Journal Article
Closed access
RGRobert C. Gibler
Robert C. Gibler
MMMaya A. Marzouk
Maya A. Marzouk
JPJames Peugh
James Peugh
BRBrooke L. Reidy
Brooke L. Reidy
MEMichelle M. Ernst
Michelle M. Ernst
SSShalonda K. Slater
Shalonda K. Slater
This cross-sectional observational study retrospectively examined clinical data collected from adolescents and young adults (AYAs) seeking care in a specialty headache clinic. We characterized participants' headache characteristics and psychological functioning and examined the association between self-reported anxiety and depressive symptoms and headache frequency, severity, and disability. During their clinic visit, AYAs (M age = 18.36; range = 14-32, 79.5% female) completed an intake questionnaire and reported about their headache characteristics (i.e., frequency, severity, and duration of symptoms in months), mental health history (i.e., previous diagnosis of an anxiety or depressive disorder), and utilization of emergency department (ED) services for migraine. AYAs also completed psychometrically validated screening tools for anxiety and depressive symptoms (i.e., the GAD-7 and PHQ-9). We computed descriptive statistics and examined associations among scores on psychological measures and headache characteristics, including migraine-related disability. We also tested whether individuals with clinically elevated GAD-7 and PHQ-9 scores had higher levels of disability relative to those with fewer/subclinical levels of anxiety and depressive symptoms. Participants (N = 283) reported more than 19 headache days per month on average, with more than 90% describing their average headache intensity as moderate or severe. Nearly half of AYAs reported severe headache-related disability. Approximately one-quarter of AYAs reported a previous diagnosis anxiety or depressive disorder diagnosis, and more than one-third scored above clinical cutoffs on the PHQ-9 and GAD-7. Higher scores on both psychological screening instruments were associated with greater headache frequency. More than 10% of patients endorsed current suicidal ideation; this was not related to headache-related disability. Participants reported a high degree of ED utilization for headache; these rates were unrelated to endorsement of psychological comorbidities. In this sample of AYAs, headache characteristics were generally unrelated to scores on measures on psychological functioning. However, the observed rates of clinically elevated anxiety/depressive symptoms and suicidality in this sample of AYAs underscore the importance of screening for psychological comorbidities in neurology clinics that serve this age group, irrespective of self-reported disability. Results also emphasize the need to expand access to behavioral health services for AYAs with headache disorders and the importance of incorporating a biopsychosocial perspective to the transition of health care from pediatrics to adult neurology practice.

27 June 2024 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
MMMaya A. Marzouk
Maya A. Marzouk
DBDawn C. Buse
Dawn C. Buse
DKDina Karvounides
Dina Karvounides
SPScott W. Powers
Scott W. Powers
ESElizabeth K. Seng
Elizabeth K. Seng

8 September 2026 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
PDF file
EFEstée C. H. Feldman
Estée C. H. Feldman
MEMichelle M. Ernst
Michelle M. Ernst
MMMaya A. Marzouk
Maya A. Marzouk
RGRobert C. Gibler
Robert C. Gibler
BRBrooke L. Reidy
Brooke L. Reidy
TIthe REACH Study Investigators
the REACH Study Investigators
Migraine is one of the most common chronic health problems in children and adolescents, resulting in high levels of functional disability. Symptoms frequently persist into and impact the course of adulthood for affected individuals. Current practice recommendations include a combined therapy approach of preventive medication and cognitive behavioral therapy (CBT); however, no trials have systematically assessed whether a combined therapy approach is superior to a cognitive behavioral monotherapy intervention. The REACH (Responding With Evidence and Access for Childhood Headaches) trial will compare the impact of a CBT monotherapy to a combined treatment for prevention of migraine in youth, while addressing barriers to CBT access by utilizing a teletherapy approach. The study will include youth with migraine between the ages of 10 and 17 years from 15 sites across the United States, who will be randomly assigned to a CBT + pill (amitriptyline) group or CBT‐alone group. Both groups will complete six sessions of telehealth CBT, as well as three booster sessions, over the course of 6 months. Participants will report on headache and migraine frequency and related disability via a daily headache diary before (28‐day baseline), during, and after completion of the intervention (the last 28 days on the protocol). The CBT + pill group will also undergo a dose titration of clinically prescribed amitriptyline throughout the active treatment phase. Primary treatment outcomes are a ≥50% reduction in headache days and reduction in migraine‐related disability (i.e., Pediatric Migraine Disability Assessment score ≤20). Findings of the REACH study may confirm current practice guidelines or provide evidence of comparable effectiveness of combined therapy and CBT monotherapy for prevention of migraine. This trial is designed to reinforce current guidelines for preventive headache management strategies in youth with migraine. The study will also advance knowledge by determining whether CBT alone, without the potential side effects of medication, is sufficient.